Selected research
Industry Research
Chronic Urticaria Or Hives Drug Industry Research Report 2026
Market perspective
The global Chronic Urticaria Or Hives Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Chronic Urticaria Or Hives Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Chronic Urticaria Or Hives Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Chronic Urticaria Or Hives Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Chronic Urticaria Or Hives Drug include Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Panacea Biotec Limited, Mycenax Biotech Inc., Mabtech Limited, J Uriach Y Compania, S.A., GlaxoSmithKline Plc and Genentech, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Chronic Urticaria Or Hives Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chronic Urticaria Or Hives Drug Market by Company
Novartis AG
Merck & Co., Inc.
AstraZeneca Plc
Panacea Biotec Limited
Mycenax Biotech Inc.
Mabtech Limited
J Uriach Y Compania, S.A.
GlaxoSmithKline Plc
Genentech, Inc.
Faes Farma, SA
ELORAC, Inc.
Biofrontera AG
Chronic Urticaria Or Hives Drug Segment by Type
BF-Derm-1
GDC-0853
GSK-2646264
Bilastine
Others
Chronic Urticaria Or Hives Drug Segment by Application
Clinic
Hospital
Others
Chronic Urticaria Or Hives Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Urticaria Or Hives Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Urticaria Or Hives Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Urticaria Or Hives Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Chronic Urticaria Or Hives Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Chronic Urticaria Or Hives Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Chronic Urticaria Or Hives Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- BF-Derm-1
- GDC-0853
- GSK-2646264
- Bilastine
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca Plc
- Panacea Biotec Limited
- Mycenax Biotech Inc.
- Mabtech Limited
- J Uriach Y Compania, S.A.
- GlaxoSmithKline Plc
- Genentech, Inc.
- Faes Farma, SA
- ELORAC, Inc.
- Biofrontera AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Chronic Urticaria Or Hives Drug Market Size (2021-2032)
- 2.2.2 Global Chronic Urticaria Or Hives Drug Sales (2021-2032)
- 2.2.3 Global Chronic Urticaria Or Hives Drug Market Average Price (2021-2032)
- 2.3 Chronic Urticaria Or Hives Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 BF-Derm-1
- 2.3.3 GDC-0853
- 2.3.4 GSK-2646264
- 2.3.5 Bilastine
- 2.3.6 Others
- 2.4 Chronic Urticaria Or Hives Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Chronic Urticaria Or Hives Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Chronic Urticaria Or Hives Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Chronic Urticaria Or Hives Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Chronic Urticaria Or Hives Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Chronic Urticaria Or Hives Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Chronic Urticaria Or Hives Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Chronic Urticaria Or Hives Drug, Product Type & Application
- 3.8 Global Manufacturers of Chronic Urticaria Or Hives Drug, Established Date
- 3.9 Global Chronic Urticaria Or Hives Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Chronic Urticaria Or Hives Drug Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 AstraZeneca Plc
- 4.3.1 AstraZeneca Plc Company Information
- 4.3.2 AstraZeneca Plc Business Overview
- 4.3.3 AstraZeneca Plc Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AstraZeneca Plc Chronic Urticaria Or Hives Drug Product Portfolio
- 4.3.5 AstraZeneca Plc Recent Developments
- 4.4 Panacea Biotec Limited
- 4.4.1 Panacea Biotec Limited Company Information
- 4.4.2 Panacea Biotec Limited Business Overview
- 4.4.3 Panacea Biotec Limited Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Panacea Biotec Limited Chronic Urticaria Or Hives Drug Product Portfolio
- 4.4.5 Panacea Biotec Limited Recent Developments
- 4.5 Mycenax Biotech Inc.
- 4.5.1 Mycenax Biotech Inc. Company Information
- 4.5.2 Mycenax Biotech Inc. Business Overview
- 4.5.3 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 4.5.5 Mycenax Biotech Inc. Recent Developments
- 4.6 Mabtech Limited
- 4.6.1 Mabtech Limited Company Information
- 4.6.2 Mabtech Limited Business Overview
- 4.6.3 Mabtech Limited Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Mabtech Limited Chronic Urticaria Or Hives Drug Product Portfolio
- 4.6.5 Mabtech Limited Recent Developments
- 4.7 J Uriach Y Compania, S.A.
- 4.7.1 J Uriach Y Compania, S.A. Company Information
- 4.7.2 J Uriach Y Compania, S.A. Business Overview
- 4.7.3 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Product Portfolio
- 4.7.5 J Uriach Y Compania, S.A. Recent Developments
- 4.8 GlaxoSmithKline Plc
- 4.8.1 GlaxoSmithKline Plc Company Information
- 4.8.2 GlaxoSmithKline Plc Business Overview
- 4.8.3 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Product Portfolio
- 4.8.5 GlaxoSmithKline Plc Recent Developments
- 4.9 Genentech, Inc.
- 4.9.1 Genentech, Inc. Company Information
- 4.9.2 Genentech, Inc. Business Overview
- 4.9.3 Genentech, Inc. Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Genentech, Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 4.9.5 Genentech, Inc. Recent Developments
- 4.10 Faes Farma, SA
- 4.10.1 Faes Farma, SA Company Information
- 4.10.2 Faes Farma, SA Business Overview
- 4.10.3 Faes Farma, SA Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Faes Farma, SA Chronic Urticaria Or Hives Drug Product Portfolio
- 4.10.5 Faes Farma, SA Recent Developments
- 4.11 ELORAC, Inc.
- 4.11.1 ELORAC, Inc. Company Information
- 4.11.2 ELORAC, Inc. Business Overview
- 4.11.3 ELORAC, Inc. Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ELORAC, Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 4.11.5 ELORAC, Inc. Recent Developments
- 4.12 Biofrontera AG
- 4.12.1 Biofrontera AG Company Information
- 4.12.2 Biofrontera AG Business Overview
- 4.12.3 Biofrontera AG Chronic Urticaria Or Hives Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Biofrontera AG Chronic Urticaria Or Hives Drug Product Portfolio
- 4.12.5 Biofrontera AG Recent Developments
5 Global Chronic Urticaria Or Hives Drug Market Scenario by Region
- 5.1 Global Chronic Urticaria Or Hives Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Chronic Urticaria Or Hives Drug Sales by Region: 2021-2032
- 5.2.1 Global Chronic Urticaria Or Hives Drug Sales by Region: 2021-2026
- 5.2.2 Global Chronic Urticaria Or Hives Drug Sales by Region: 2027-2032
- 5.3 Global Chronic Urticaria Or Hives Drug Revenue by Region: 2021-2032
- 5.3.1 Global Chronic Urticaria Or Hives Drug Revenue by Region: 2021-2026
- 5.3.2 Global Chronic Urticaria Or Hives Drug Revenue by Region: 2027-2032
- 5.4 North America Chronic Urticaria Or Hives Drug Market Facts & Figures by Country
- 5.4.1 North America Chronic Urticaria Or Hives Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Chronic Urticaria Or Hives Drug Sales by Country (2021-2032)
- 5.4.3 North America Chronic Urticaria Or Hives Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Chronic Urticaria Or Hives Drug Market Facts & Figures by Country
- 5.5.1 Europe Chronic Urticaria Or Hives Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Chronic Urticaria Or Hives Drug Sales by Country (2021-2032)
- 5.5.3 Europe Chronic Urticaria Or Hives Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Chronic Urticaria Or Hives Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Chronic Urticaria Or Hives Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Chronic Urticaria Or Hives Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Chronic Urticaria Or Hives Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Chronic Urticaria Or Hives Drug Market Facts & Figures by Country
- 5.7.1 South America Chronic Urticaria Or Hives Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Chronic Urticaria Or Hives Drug Sales by Country (2021-2032)
- 5.7.3 South America Chronic Urticaria Or Hives Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Chronic Urticaria Or Hives Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Chronic Urticaria Or Hives Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Chronic Urticaria Or Hives Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Chronic Urticaria Or Hives Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Chronic Urticaria Or Hives Drug Sales by Type (2021-2032)
- 6.1.1 Global Chronic Urticaria Or Hives Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Chronic Urticaria Or Hives Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Chronic Urticaria Or Hives Drug Revenue by Type (2021-2032)
- 6.2.1 Global Chronic Urticaria Or Hives Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Chronic Urticaria Or Hives Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Chronic Urticaria Or Hives Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Chronic Urticaria Or Hives Drug Sales by Application (2021-2032)
- 7.1.1 Global Chronic Urticaria Or Hives Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Chronic Urticaria Or Hives Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Chronic Urticaria Or Hives Drug Revenue by Application (2021-2032)
- 7.2.1 Global Chronic Urticaria Or Hives Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Chronic Urticaria Or Hives Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Chronic Urticaria Or Hives Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Chronic Urticaria Or Hives Drug Value Chain Analysis
- 8.1.1 Chronic Urticaria Or Hives Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Chronic Urticaria Or Hives Drug Production Mode & Process
- 8.2 Chronic Urticaria Or Hives Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Chronic Urticaria Or Hives Drug Distributors
- 8.2.3 Chronic Urticaria Or Hives Drug Customers
9 Global Chronic Urticaria Or Hives Drug Analyzing Market Dynamics
- 9.1 Chronic Urticaria Or Hives Drug Industry Trends
- 9.2 Chronic Urticaria Or Hives Drug Industry Drivers
- 9.3 Chronic Urticaria Or Hives Drug Industry Opportunities and Challenges
- 9.4 Chronic Urticaria Or Hives Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst